Lubrizol will participate in WHX Dubai 2026, spotlighting its expanding medical device manufacturing capabilities and new investments in India, including a high-precision medical tubing facility in Chennai set to open mid-2026.
.jpeg)
Union Health Ministry drafts rules mandating blue strip on antimicrobial drugs to curb AMR. Public comments invited; aligns with PM Modi’s antibiotic safety emphasis.
Sanofi’s amlitelimab, a promising treatment for moderate-to-severe atopic dermatitis (AD), has shown robust results in two global Phase 3 studies. The findings, along with a favorable safety profile, highlight its potential to improve patients’ quali
Sun Pharmaceutical Industries has received DCGI approval for Noveltreat, a generic semaglutide injection designed to help with weight management. The treatment offers a cost-effective solution to combat obesity and related conditions.
Moderna and Merck’s personalized skin cancer vaccine shows a 49% reduction in recurrence risk after five years, offering new hope for high-risk melanoma patients.
Pfizer exits ViiV Healthcare in $1.9B deal, Shionogi doubles stake to 21.7%, while GSK retains majority, advancing long-acting HIV treatments and prevention.
Novartis announced today that the FDA has granted Breakthrough Therapy designation to ianalumab for Sjogren’s disease, strengthening its path toward becoming the first targeted treatment for this autoimmune condition.
Illumina, Inc. has announced the launch of the Illumina Billion Cell Atlas, a large-scale genomic dataset intended to strengthen the scientific foundation of drug discovery and biomedical research. The announcement was made from San Diego on Thurs...
Venus Remedies has received regulatory approval in Indonesia for ceftazidime+avibactam, enabling the country’s first generic launch and marking the company’s entry into the anti-infective segment in the key ASEAN market.
Bristol Myers Squibb today reported positive Phase 3 results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data come from the Phase 3 SCOUT-HCM trial, the first study of a cardiac myosin inhibitor...
.jpg)
, CDSCO.jpg)